blindness from glp 1 GLP-1 meds and vision: what the scary headlines DON'T say Researchers Find Small Increased Risk
Description
The new sodium-glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists are potential game changers for people with type 2 diabetes

Lower titration steps were not intended as long-term endpoints

Contact our pharmacist team

22,23 On the other hand, the role of lifestyle modification should not be diminished

GLP-1 receptor
